217 related articles for article (PubMed ID: 4210148)
1. Uptake of glibornuride by microdissected pancreatic islets.
Täljedal IB
Horm Res; 1974; 5(4):211-6. PubMed ID: 4210148
[No Abstract] [Full Text] [Related]
2. Different amounts of insulin secretion following an equal total decrease of blood glucose as an indication of possible extrapancreatic activities of different sulfonylurea drugs.
Beyer J; Haupt E; Cordes U; Kutschera J; Schöffling K
Horm Metab Res; 1973 Jan; 5(1):9-13. PubMed ID: 4196346
[No Abstract] [Full Text] [Related]
3. [Pharmacological comparison between tolbutamide and two second generation hypoglycemic sulfonylureas (glibenclamide and glisoxepide)].
Loubatières A; Ribes G; Mariani MM; Alric R
Acta Diabetol Lat; 1973; 10(2):261-82. PubMed ID: 4200420
[No Abstract] [Full Text] [Related]
4. Factors affecting the uptake of glibenclamide in microdissected pancreatic islets rich in beta-cells.
Hellman B
Pharmacology; 1974; 11(5):257-67. PubMed ID: 4212009
[No Abstract] [Full Text] [Related]
5. [Studies on new sulfonylurea derivatives and their metabolites in isolated Langerhans's islets of the rat pancreas (author's transl].
Krause U; Puchinger H; Wacker A
Arzneimittelforschung; 1975 Aug; 25(8):1231-3. PubMed ID: 810148
[TBL] [Abstract][Full Text] [Related]
6. [Extrapancreatic effects of sulfonylurea compounds. IV. Increase of the effect of insulin due to tolbutamide, glibornuride, and glibenclamide in vitro].
Beyer J; Gather W; Schöffling K
Arzneimittelforschung; 1972 Dec; 22():Suppl 12A:2179. PubMed ID: 4198966
[No Abstract] [Full Text] [Related]
7. Dynamics of sulfonylurea-induced insulin release from the isolated perfused rat pancreas.
Gotfredsen CF
Diabetologia; 1976 Aug; 12(4):339-42. PubMed ID: 134920
[TBL] [Abstract][Full Text] [Related]
8. [Extrapancreatic effects of sulfonylurea compounds. 3. Studies on the additional blood sugar decreasing and antilipolytic effect of tolbutamide, glibornuride, and glibenclamide on completely pancreatectomized dogs, chronically treated with insulin during acute experiment and following pretreatment with sulfonylurea compounds using small doses of sulfonylurea].
Beyer J; Cordes U; Sell G; Schöffling K
Arzneimittelforschung; 1972 Dec; 22():Suppl 12A:2176. PubMed ID: 4198965
[No Abstract] [Full Text] [Related]
9. Inhibition of K+ channels and stimulation of insulin secretion by the sulfonylurea, glimepiride, in relation to its membrane binding in pancreatic islets.
Schwanstecher M; Mnner K; Panten U
Pharmacology; 1994 Aug; 49(2):105-11. PubMed ID: 7972319
[TBL] [Abstract][Full Text] [Related]
10. [Effect of a new sulfonylurea on insulin and glucagon secretion in the isolated perfused pancreas].
Laube H; Fussgänger RD; Schröder KE; Pfeiffer EF
Arzneimittelforschung; 1972 Dec; 22():Suppl 12A:2186. PubMed ID: 4579624
[No Abstract] [Full Text] [Related]
11. The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs.
Zhang CL; Katoh M; Shibasaki T; Minami K; Sunaga Y; Takahashi H; Yokoi N; Iwasaki M; Miki T; Seino S
Science; 2009 Jul; 325(5940):607-10. PubMed ID: 19644119
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological comparison between tolbutamide and two second generation hypoglycemic sulfonylureas (glibenclamide and glisoxepide).
Loubatiéres A; Mariani MM; Ribes G; Alric R
Acta Diabetol Lat; 1973; 10(2):261-82. PubMed ID: 4200675
[No Abstract] [Full Text] [Related]
13. Glucose modulates the amount, but not the kinetics, of insulin released by sulfonylureas.
Gregorio F; Ambrosi F; Filipponi P; Cristallini S; Santeusanio F
J Diabetes Complications; 1994; 8(4):204-12. PubMed ID: 7833495
[TBL] [Abstract][Full Text] [Related]
14. [Current concepts of the pancreatic and extrapancreatic mechanisms of the action of peroral hypoglycemic sulfonylurea preparations].
Poltorak VV; Gladkikh AI
Probl Endokrinol (Mosk); 1985; 31(2):76-85. PubMed ID: 2859589
[No Abstract] [Full Text] [Related]
15. Therapeutical concentrations of tolbutamide, glibenclamide, gliclazide and gliquidone at different glucose levels: in vitro effects on pancreatic A- and B-cell function.
Gregorio F; Ambrosi F; Cristallini S; Pedetti M; Filipponi P; Santeusanio F
Diabetes Res Clin Pract; 1992 Dec; 18(3):197-206. PubMed ID: 1289021
[TBL] [Abstract][Full Text] [Related]
16. [Thyroid gland function of patients with diabetes in long-term use of glibornuride].
Reinwein D
Arzneimittelforschung; 1972 Dec; 22():Suppl 12A:2221. PubMed ID: 4125093
[No Abstract] [Full Text] [Related]
17. Metabolic, cationic and secretory effects of hypoglycemic sulfonylureas in pancreatic islets.
Kawazu S; Sener A; Couturier E; Malaisse WJ
Naunyn Schmiedebergs Arch Pharmacol; 1980 Jul; 312(3):277-83. PubMed ID: 6995864
[TBL] [Abstract][Full Text] [Related]
18. [The effect of oral antidiabetics on the biosynthesis of proinsulin in the rat].
Tjioe TO; Wacker A
Arzneimittelforschung; 1972 Nov; 22(11):1890-2. PubMed ID: 4633587
[No Abstract] [Full Text] [Related]
19. The effect of tolbutamide and glibenclamide on the incorporation of ( 3 H)leucine and on the conversion of proinsulin to insulin in isolated pancreatic islets.
Schatz H; Maier V; Hinz M; Nierle C; Pfeiffer EF
FEBS Lett; 1972 Oct; 26(1):237-40. PubMed ID: 4629118
[No Abstract] [Full Text] [Related]
20. Exchange protein directly activated by cyclic AMP isoform 2 is not a direct target of sulfonylurea drugs.
Tsalkova T; Gribenko AV; Cheng X
Assay Drug Dev Technol; 2011 Feb; 9(1):88-91. PubMed ID: 21133673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
